Acrux Pharmaceuticals News and Activities

Acrux Pharmaceuticals is a company listed under the stock ticker ACXP (US).

View the org chart displaying its 9 main executives

Most searched biographies at Acrux Pharmaceuticals

• David Luci, President and Chief Executive Officer
• Robert DeLuccia, Executive Chairman of the Board
• Jack Dean, Director

Create your alert
to follow the executive moves at Acrux Pharmaceuticals.

Acrux Pharmaceuticals has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Acrux Pharmaceuticals

• Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
• Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
• Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
• Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
• Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
• Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
• Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
• Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update
• Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
• Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update
• View more press releases Close

Social media about Acrux Pharmaceuticals

• Acrux Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Acrux Pharmaceuticals on LinkedIn, X (Twitter) & YouTube